Education
About Us
Working with TipRanks
Follow Us
Nurix Therapeutics (NRIX)
NASDAQ:NRIX
NRIX Stock Chart & Stats
$14.43
$0.42(2.22%)
At close: 4:00 PM EST
$14.43
$0.42(2.22%)
Day’s Range― - ―
52-Week Range$8.18 - $22.50
Previous CloseN/A
Volume302.00K
Average Volume (3M)986.91K
Market Cap
$1.48B
Enterprise Value$1.06B
Total Cash (Recent Filing)$592.94M
Total Debt (Recent Filing)$55.73M
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Apr 14, 2026EPS Estimate
-0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding102,843,010
10 Day Avg. Volume1,416,177
30 Day Avg. Volume986,906
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)2.72
Price to Sales (P/S)17.45
P/FCF Ratio-5.56
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue12.61
Enterprise Value/Gross Profit-14.43
Enterprise Value/Ebitda-4.12
Forecast
1Y Price Target
$31.00Price Target Upside114.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.13
Revenue Forecast (FY)$57.76M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy In CLLDurable responses in heavily pretreated chronic lymphocytic leukemia patients suggest bexdeg could become a leading option in the post-BTK inhibitor setting, enhancing commercial prospects.
Pivotal Clinical DevelopmentInitiation of the DAYBreak pivotal trial for bexdeg and plans for a head-to-head phase 3 versus a top competitor could align with regulators and support an accelerated approval pathway.
Strategic PartnershipsAdvancement of partnered programs, notably the STAT6 degrader collaboration with Sanofi, could provide meaningful upside if early clinical results are positive.
Bears Say
Clinical Proof-of-concept RiskNegative proof-of-concept for a lead candidate would substantially undermine the company's development thesis and could sharply reduce valuation.
Execution RiskReliance on multiple pivotal trials and sequential data releases increases exposure to operational setbacks and heightens near-term share volatility.
Regulatory And Commercial RiskFailure to secure regulatory approvals or weaker-than-expected market uptake would materially impair commercial opportunity and long-term revenue potential.
Nurix Therapeutics News
NRIX FAQ
What was Nurix Therapeutics’s price range in the past 12 months?
Nurix Therapeutics lowest stock price was $8.18 and its highest was $22.50 in the past 12 months.
What is Nurix Therapeutics’s market cap?
Nurix Therapeutics’s market cap is $1.48B.
When is Nurix Therapeutics’s upcoming earnings report date?
Nurix Therapeutics’s upcoming earnings report date is Apr 14, 2026 which is in 22 days.
How were Nurix Therapeutics’s earnings last quarter?
Nurix Therapeutics released its earnings results on Jan 28, 2026. The company reported -$0.82 earnings per share for the quarter, beating the consensus estimate of -$0.871 by $0.051.
Is Nurix Therapeutics overvalued?
According to Wall Street analysts Nurix Therapeutics’s price is currently Undervalued.
Does Nurix Therapeutics pay dividends?
Nurix Therapeutics does not currently pay dividends.
What is Nurix Therapeutics’s EPS estimate?
Nurix Therapeutics’s EPS estimate is -0.76.
How many shares outstanding does Nurix Therapeutics have?
Nurix Therapeutics has 102,843,010 shares outstanding.
What happened to Nurix Therapeutics’s price movement after its last earnings report?
Nurix Therapeutics reported an EPS of -$0.82 in its last earnings report, beating expectations of -$0.871. Following the earnings report the stock price went down -1.567%.
Which hedge fund is a major shareholder of Nurix Therapeutics?
Currently, no hedge funds are holding shares in NRIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nurix Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.00 (114.83% Upside)
$31.00 (114.83% Upside)
Blogger Sentiment
Bullish
NRIX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.3%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.03%
12-Months-Change
Fundamentals
Return on Equity
-57.51%
Trailing 12-Months
Asset Growth
4.02%
Trailing 12-Months
Company Description
Nurix Therapeutics
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
NRIX Stock 12 Month Forecast
Average Price Target
$31.00
▲(114.83% Upside)
Technical Analysis
Arvinas Holding Company
―
Vir Biotechnology
―
Relay Therapeutics
―
Terns Pharmaceuticals
―
Ownership Overview
0.20% Insiders
15.52% Mutual Funds
58.06% Other Institutional Investors
5.16% Public Companies and
Individual Investors